AccessibilityHelpAbout Us
Algorae Pharmaceuticals logo

Algorae Pharmaceuticals(OTC) LVCLF

Market Cap$19.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-90%
5 Year-4%
1 Year+77%
1 Month+0%
$0.01
+0.00%
+0.00Today
Algorae Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.012026-08-06
Algorae Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.012026-06-29
1 month+0%USD 0.012026-06-29
3 month+20.89%USD 0.012025-12-22
Year to date+20.89%USD 0.012025-12-22
1 year+76.85%USD 0.012025-06-11
3 year+38.41%USD 0.012023-08-04
5 year-4.02%USD 0.012021-08-03
Since inception-90.45%USD 0.102007-07-11

Algorae Pharmaceuticals Financials at a Glance

Market Cap

$19.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$0.00

Net Income (TTM)

-A$3.61M

EPS (TTM)

-$0.00

P/E Ratio

-8.68

Dividend

$0.00

Beta (Volatility)

0.55 (Low)

Price

$0.01

Volume

196,572

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Feb 24, 2026

LVCLF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Algorae Pharmaceuticals

Algorae Pharmaceuticals Limited is a pharmaceutical development company based in Melbourne, Australia, focusing on innovative living cell technologies. Established in 1987, the company is dedicated to advancing treatments for neurological and cardiovascular conditions through its diverse product pipeline.

Products and Services
  • AI-116: A combination therapy for dementia treatment
  • NTCELL: An alginate-coated capsule targeting Parkinson's disease
  • AlgaraeOS: An AI platform for predicting biopharmaceutical drug targets
Growth Outlook
  • Partnership with the University of New South Wales enhances research capabilities
  • Focus on high-demand therapeutic areas like dementia and cardiovascular health
  • Potential for significant market impact with innovative product pipeline
Financial Highlights
  • Recent quarterly net income of -$863,572 indicates ongoing investment in R&D
  • Cash and short-term investments totaled $1,882,433, providing operational flexibility
  • Current ratio of 17.99 suggests strong liquidity position
Algorae Pharmaceuticals Limited is positioned in the biotechnology sector, with a focus on developing groundbreaking therapies. The company’s commitment to research and development is evident in its substantial investment in innovative treatments, particularly for conditions with high unmet medical needs. The collaboration with academic institutions further strengthens its research capabilities, potentially leading to breakthroughs in treatment options. Financially, while the company is currently operating at a loss, the significant cash reserves provide a buffer for continued development and operational activities. The high current ratio indicates a robust liquidity position, allowing Algorae to navigate the challenges of the pharmaceutical development landscape effectively. Overall, Algorae Pharmaceuticals Limited presents a compelling opportunity for investors interested in the biotechnology sector, particularly in innovative therapeutic solutions.
AI Generated • Aug 29, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Bernard E. Tuch, PhD

Website

www.algoraepharma.com

Headquarters

Melbourne, VI 3000, AU

LVCLF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-88.14%

Return on Capital

-76.50%

Return on Assets

-61.08%

Earnings Yield

-11.52%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$19.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.03B

Volume

196.57K

Avg. Volume

4.60K

Financials (TTM)

Gross Profit

A$0.00

Operating Income

-A$4.81M

EBITDA

-A$4.34M

Operating Cash Flow

-A$1.13M

Capital Expenditure

-A$3.00

Free Cash Flow

-A$1.13M

Cash & ST Invst.

A$3.93M

Total Debt

A$0.00

Algorae Pharmaceuticals Performance Analysis

Algorae Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Algorae Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-100.0%
Q42025-06-30N/A
Q22025-12-31N/A
Q42026-06-30N/A
Algorae Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.00-37.5%
20242024-06-30AUD -0.00-20.0%
20252025-06-30AUD -0.00-62.5%
20262026-06-30AUD -0.00233.3%
Algorae Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31N/A
Q42025-06-3075.0%
Q22025-12-31100.0%
Q42026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

A$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$19.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$403.40K

N/A

Employees

48

N/A

Net Income

-A$1.95M

-201.9%

EBITDA

-A$2.10M

-388.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$3.93M

+26.5%

Total Debt

A$0.00

N/A

Accounts Receivable

A$83.36K

+187.7%

Inventory

A$180.49K

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-61.08%

N/A

Return on Invested Capital

-73.72%

N/A

Free Cash Flow

-A$617.97K

+38.7%

Operating Cash Flow

-A$617.96K

+38.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMUCEOM Pharmaceuticals Holdings, Inc.
$0.16-10.22%
DVHGFDevonian Health Group Inc.
$5.88+0.00%
LIANYLianBio
$0.06+56.99%
NYMXFNymox Pharmaceutical Corporation
$0.02+9900.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$108.80+7.67%
NOKNokia
$10.60+4.54%
DAICCid HoldCo
$5.30+163.68%
NVDANvidia
$219.34+2.54%

Questions About LVCLF

What is the current price of Algorae Pharmaceuticals?

Algorae Pharmaceuticals is trading at $0.01 per share.

What is the 52-week range for Algorae Pharmaceuticals?

Over the past 52 weeks, Algorae Pharmaceuticals has traded between $0.00 and $0.01.

How much debt does Algorae Pharmaceuticals have?

As of the most recent reporting period, Algorae Pharmaceuticals reported total debt of A$0.00.

How much cash does Algorae Pharmaceuticals have on hand?

Algorae Pharmaceuticals reported A$2.21M in cash and cash equivalents in its most recent financial results.

What is Algorae Pharmaceuticals’s dividend yield?

Algorae Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services